Lantern Pharma (NASDAQ: LTRN) has reported its second-quarter 2026 operational and financial results, showcasing significant advancements in its AI-driven oncology pipeline and the strategic establishment of Open Medicine AI (OMAI) as a separate entity. The company's focus on precision medicine and artificial intelligence continues to yield promising developments, particularly in its lead drug candidates.
One of the key highlights is the emerging data from the Phase 2 HARMONIC trial, which indicates that LP-300's progression-free survival benefit deepens with treatment duration in patients with EGFR exon 21 L858R mutations. This finding is critical as it suggests that prolonged treatment may enhance the drug's efficacy, potentially leading to better outcomes for this specific patient population. Additionally, the FDA has reviewed key protocol amendments without objection, signaling a positive regulatory environment for the trial's progression.
In Europe, the European Medicines Agency has cleared an investigator-initiated Phase 1b/2 trial of LP-184, also known as zirdafulven, in biomarker-selected advanced bladder cancer. This clearance paves the way for the drug to be tested in a new indication, expanding its potential therapeutic reach. Furthermore, the U.S. Patent and Trademark Office has issued a Notice of Allowance for a three-gene patient-selection signature for LP-184, which could enable more precise patient selection in future trials and eventual clinical use.
In August, Lantern took a major strategic step by establishing OMAI as a wholly owned subsidiary and entering into board-approved commercial licensing agreements for its multi-agentic AI co-scientist platform, previously launched as withZeta.ai. This move is designed to unlock the value of its AI technology, which is now commercially available as a subscription-based research platform for the global biomedical and drug development community. This represents a new revenue stream for the company, diversifying its income beyond traditional drug development.
Financially, Lantern reported a second-quarter loss from operations of approximately $3.5 million, a 25% improvement from the $4.7 million loss in the same period last year. Research and development expenses declined by 42% to approximately $1.8 million, reflecting increased efficiency. The net loss was approximately $7.1 million, or $0.57 per share, compared to $4.3 million, or $0.40 per share, a year earlier. The increase in net loss is largely due to approximately $3.6 million in warrant-related expenses. As of June 30, 2026, the company had cash, cash equivalents, and marketable securities totaling approximately $7.4 million, providing a runway to continue its operations.
Lantern Pharma's pipeline includes LP-184, LP-284, and LP-300, with LP-184 also being developed for pediatric CNS cancers through Starlight Therapeutics, a wholly owned CNS-focused subsidiary. The company operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas. The establishment of OMAI and the commercial launch of withZeta.ai underscore Lantern's commitment to leveraging AI to accelerate oncology drug development and create value for shareholders.
For more details, the full press release is available at https://nnw.fm/m9pULA. The latest news and updates on Lantern Pharma can be found in the company's newsroom at https://nnw.fm/LTRN.
